Assessment of clinical performance without adequate analytical validation: A prescription for confusion

Lawrence K. Oliver, Nikolay Voskoboev, Don Heser, Joseph P. McConnell, Shannon Hodel-Hanson, Heidi Callanan, Allan S Jaffe

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: Lp-PLA2 is a biomarker with promise for predicting cardiac risk. The lack of reproducible results has limited its use. In evaluating a new reagent kit, we investigated conditions for optimal reproducibility. Methods: The Auto-PLAC reagents were evaluated on the Cobas instrument. Performance characteristics, stability, and population ranges were determined. Results: Analytical performance characteristics replicated manufacturer's claims. The stability profile of the analyte was unusual, with increasing results observed with storage at 4 °C or - 20 °C. Only storage at -70 °C gave acceptable stability. Population median values with properly preserved samples were much lower than the cut off previously validated for increased risk. Conclusions: It is postulated that variability in specimen handling was a major contributor to the lack of traceability of the current reagents to the earlier clinical studies demonstrating its utility. We are now unsure how to identify reliable criteria for result interpretation.

Original languageEnglish (US)
Pages (from-to)1247-1252
Number of pages6
JournalClinical Biochemistry
Volume44
Issue number14-15
DOIs
StatePublished - Oct 2011

Fingerprint

Prescriptions
1-Alkyl-2-acetylglycerophosphocholine Esterase
Specimen Handling
Biomarkers
Population Characteristics
Population
5'-palmitoyl cytarabine
Clinical Studies

Keywords

  • Automation
  • Cardiac risk assessment
  • Phospholipase
  • Reference range
  • Stability
  • Traceability

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Assessment of clinical performance without adequate analytical validation : A prescription for confusion. / Oliver, Lawrence K.; Voskoboev, Nikolay; Heser, Don; McConnell, Joseph P.; Hodel-Hanson, Shannon; Callanan, Heidi; Jaffe, Allan S.

In: Clinical Biochemistry, Vol. 44, No. 14-15, 10.2011, p. 1247-1252.

Research output: Contribution to journalArticle

Oliver, LK, Voskoboev, N, Heser, D, McConnell, JP, Hodel-Hanson, S, Callanan, H & Jaffe, AS 2011, 'Assessment of clinical performance without adequate analytical validation: A prescription for confusion', Clinical Biochemistry, vol. 44, no. 14-15, pp. 1247-1252. https://doi.org/10.1016/j.clinbiochem.2011.07.005
Oliver, Lawrence K. ; Voskoboev, Nikolay ; Heser, Don ; McConnell, Joseph P. ; Hodel-Hanson, Shannon ; Callanan, Heidi ; Jaffe, Allan S. / Assessment of clinical performance without adequate analytical validation : A prescription for confusion. In: Clinical Biochemistry. 2011 ; Vol. 44, No. 14-15. pp. 1247-1252.
@article{ee3eb00354384574b413e1eba6faab35,
title = "Assessment of clinical performance without adequate analytical validation: A prescription for confusion",
abstract = "Objectives: Lp-PLA2 is a biomarker with promise for predicting cardiac risk. The lack of reproducible results has limited its use. In evaluating a new reagent kit, we investigated conditions for optimal reproducibility. Methods: The Auto-PLAC reagents were evaluated on the Cobas instrument. Performance characteristics, stability, and population ranges were determined. Results: Analytical performance characteristics replicated manufacturer's claims. The stability profile of the analyte was unusual, with increasing results observed with storage at 4 °C or - 20 °C. Only storage at -70 °C gave acceptable stability. Population median values with properly preserved samples were much lower than the cut off previously validated for increased risk. Conclusions: It is postulated that variability in specimen handling was a major contributor to the lack of traceability of the current reagents to the earlier clinical studies demonstrating its utility. We are now unsure how to identify reliable criteria for result interpretation.",
keywords = "Automation, Cardiac risk assessment, Phospholipase, Reference range, Stability, Traceability",
author = "Oliver, {Lawrence K.} and Nikolay Voskoboev and Don Heser and McConnell, {Joseph P.} and Shannon Hodel-Hanson and Heidi Callanan and Jaffe, {Allan S}",
year = "2011",
month = "10",
doi = "10.1016/j.clinbiochem.2011.07.005",
language = "English (US)",
volume = "44",
pages = "1247--1252",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "14-15",

}

TY - JOUR

T1 - Assessment of clinical performance without adequate analytical validation

T2 - A prescription for confusion

AU - Oliver, Lawrence K.

AU - Voskoboev, Nikolay

AU - Heser, Don

AU - McConnell, Joseph P.

AU - Hodel-Hanson, Shannon

AU - Callanan, Heidi

AU - Jaffe, Allan S

PY - 2011/10

Y1 - 2011/10

N2 - Objectives: Lp-PLA2 is a biomarker with promise for predicting cardiac risk. The lack of reproducible results has limited its use. In evaluating a new reagent kit, we investigated conditions for optimal reproducibility. Methods: The Auto-PLAC reagents were evaluated on the Cobas instrument. Performance characteristics, stability, and population ranges were determined. Results: Analytical performance characteristics replicated manufacturer's claims. The stability profile of the analyte was unusual, with increasing results observed with storage at 4 °C or - 20 °C. Only storage at -70 °C gave acceptable stability. Population median values with properly preserved samples were much lower than the cut off previously validated for increased risk. Conclusions: It is postulated that variability in specimen handling was a major contributor to the lack of traceability of the current reagents to the earlier clinical studies demonstrating its utility. We are now unsure how to identify reliable criteria for result interpretation.

AB - Objectives: Lp-PLA2 is a biomarker with promise for predicting cardiac risk. The lack of reproducible results has limited its use. In evaluating a new reagent kit, we investigated conditions for optimal reproducibility. Methods: The Auto-PLAC reagents were evaluated on the Cobas instrument. Performance characteristics, stability, and population ranges were determined. Results: Analytical performance characteristics replicated manufacturer's claims. The stability profile of the analyte was unusual, with increasing results observed with storage at 4 °C or - 20 °C. Only storage at -70 °C gave acceptable stability. Population median values with properly preserved samples were much lower than the cut off previously validated for increased risk. Conclusions: It is postulated that variability in specimen handling was a major contributor to the lack of traceability of the current reagents to the earlier clinical studies demonstrating its utility. We are now unsure how to identify reliable criteria for result interpretation.

KW - Automation

KW - Cardiac risk assessment

KW - Phospholipase

KW - Reference range

KW - Stability

KW - Traceability

UR - http://www.scopus.com/inward/record.url?scp=80052934561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052934561&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2011.07.005

DO - 10.1016/j.clinbiochem.2011.07.005

M3 - Article

C2 - 21787764

AN - SCOPUS:80052934561

VL - 44

SP - 1247

EP - 1252

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 14-15

ER -